- Home
- GSL vs SNY Comparison
GSL vs SNY Comparison
Compare GSL & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GSL | SNY |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | Greece | France |
| Employees | 11 | 74846 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 116.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GSL | SNY |
|---|---|---|
| Price | $37.01 | $43.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $43.50 | ★ $61.50 |
| AVG Volume (30 Days) | 395.9K | ★ 4.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.68% | 3.66% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3.01 |
| Revenue Next Year | N/A | $5.80 |
| P/E Ratio | ★ $3.49 | $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.73 | $43.51 |
| 52 Week High | $41.40 | $59.17 |
Technical Indicators
Market Signals| Indicator | GSL | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 40.77 | 31.35 |
| Support Level | $36.67 | N/A |
| Resistance Level | $38.52 | $48.97 |
| Average True Range (ATR) | 1.25 | 0.69 |
| MACD | -0.42 | -0.35 |
| Stochastic Oscillator | 8.03 | 2.66 |
Price Performance
Historical ComparisonAbout GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.